在动物毒症模型中,固酶3抑制减轻了毒症的进展
Junior Garcia Oliveira1, Gustavo Ferreira Alves2, Elaine Leocádia Anton3
1Department of Pharmacology, Universidade Federal de Santa Catarina, Santa Catarina, Brazil; Department of Pharmaceutical Sciences, Universidade Estadual de Ponta Grossa, Paraná, Brazil; LAQV/REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Life sciences
|January 26, 2026
概括
在败血症模型中,用西洛斯塔抑制固酶3 (PDE3) 抑制改善了循环腺单酸盐 (cAMP) 水平,减少了炎症,并提高了生存率,特别是在与抗生素结合时.
科学领域:
- 生物医学研究的研究.
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- 败血症是一种危及生命的疾病,其特征是免疫反应失调和细胞内信号破坏.
- 像cAMP和cGMP这样的循环核酸在细胞功能中起着至关重要的作用,并且在败血症期间受到影响.
- 败血症的高死亡率强调了需要有效的治疗干预措施.
研究的目的:
- 评估使用西洛斯塔对毒症中循环核酸水平的酸化酶3 (PDE3) 抑制的影响.
- 在实验性败血症模型中评估西洛斯塔对心血管,血液动力学,炎症和生存参数的影响.
- 确定抑制PDE3作为治疗毒症管理的治疗策略的潜力.
主要方法:
- 在大鼠中,通过结和穿孔 (CLP) 诱导了败血症.
- 基洛斯塔佐尔 (15 mg/kg) 或载体是在CLP后6小时内给药的.
- 心血管,炎症,器官损伤和生存参数在CLP后24小时内和120小时内被评估.
主要成果:
- 败血症导致低血压,低心率,血流受损,全身炎症和高死亡率.
- 抑制PDE3增加了血和骨肌肉中的cAMP水平,改善了脏血流,并减少了炎症.
- 奇洛斯塔与抗生素相结合,在早期发作的败血症中降低了死亡风险,尽管有一些心脏过载效应.
结论:
- 用西洛斯塔抑制PDE3显示出通过调节cAMP水平来控制败血症的潜力.
- 这种方法可能有助于防止败血症进展为败血症休克.
- 对PDE3抑制的进一步研究可能为败血症治疗提供细胞效益.
相关概念视频
00:46Feedback Inhibition
57.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
594
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
594
02:07Tumor Progression
7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
01:30Enzyme Inhibition
91.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.9K
03:03mTOR Signaling and Cancer Progression
4.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.7K
02:34Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K